CollPlant Biotechnologies Reports Second Quarter (Q2) 2020 Financial Results
CollPlant (NASDAQ: CLGN) reported Q2 2020 revenues of $823,000, marking a 36% increase from $606,000 in Q2 2019. The comprehensive loss was $2.0 million on a GAAP basis, equating to $0.28 per share. Cash reserves stood at $3.7 million. The company is advancing its rhCollagen platform and partnering with United Therapeutics to address organ shortages. Additionally, it plans to launch new dermal fillers and expand its workforce. Operating expenses increased by 5% YoY, while the gross profit declined to $75,000.
- Revenues increased by 36% year-over-year to $823,000.
- Strong cash position with $3.7 million in cash and cash equivalents.
- Partnership with United Therapeutics for 3D bioprinting of organs.
- Plans to introduce next-generation photocurable dermal fillers.
- Comprehensive loss expanded to $2.0 million from $1.2 million YoY.
- Gross profit decreased by $68,000 compared to Q2 2019.
- Operating loss increased by 6% to $1.9 million.
REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.
CollPlant reported revenues of
"We continue to make major strides in revolutionizing the fields of regenerative and aesthetic medicine through our first-in-class, recombinant human collagen (rhCollagen) platform technology. First, we are partnering with United Therapeutics Corporation (NASDAQ: UTHR) in efforts to address global organ shortages. We plan to leverage this experience in 3D bioprinting of lung scaffolds to explore other life-saving organs and tissues in the future," stated Yehiel Tal, the Chief Executive Officer of CollPlant. "Second, the combination of hyaluronic acid and rhCollagen in our next-generation, regenerative, photocurable dermal fillers will provide superior skin rejuvenation inclusive of the ability to inject into deep wrinkles, as well as other key attributes. Moreover, we are looking forward to sharing new data on our innovative photocurable dermal fillers and additional updates on our breast implant product pipeline at the exclusive Science of Aging Virtual Symposium 2020, which will be held digitally on September 16, 2020. Third, we continue to abide by Israeli Health Ministry guidelines for optimal protection of our employees. To accommodate heightened social distancing policies amid the ongoing pandemic, we have concentrated efforts on amplifying corporate visibility through a stronger online and social media presence. Finally, we remain committed to bolstering our workforce with brilliant scientists and support staff from prestigious institutions here in Israel. We are opportunistic about establishing relationships with new strategic partners who can support our pipeline development efforts."
Financial Results
Second Quarter 2020 Financial Results on US GAAP basis ("GAAP")
Revenues for the three months ended June 30, 2020 increased by
Cost of revenue was
The Company's gross profit for the three months ended June 30, 2020 decreased by
Total operating expenses for the three months ended June 30, 2020 were
Operating loss for the three months ended June 30, 2020 was
Financial expense, net for the three months ended June 30, 2020 was
Comprehensive loss for the second quarter of 2020 was
Cash used in operating activities during the six months ended June 30, 2020 was
Cash used in investing activities during the six months ended June 30, 2020 was
Cash provided by financing activities during the six months ended June 30, 2020 was
Second Quarter 2020 Financial Results on Non-US GAAP Basis ("non-GAAP")
On a non-GAAP basis, the operating expenses for the second quarter of 2020 were
Comprehensive loss for the second quarter of 2020 was
Non-GAAP measures exclude certain non-cash expenses. The table on page 10 includes a reconciliation of the Company's GAAP results to non-GAAP results. The reconciliation reflects non-cash expenses in the amount of
Use of Non-GAAP Measures
This press release contains certain non-GAAP financial measures for operating costs and expenses, operating loss, comprehensive loss and basic and diluted comprehensive loss per share that exclude the effects of non-cash expense for fair market value attributed to change in fair value of financial instruments, share-based compensation to employees, directors and consultants, and change in operating lease accounts. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance that enhances management's and investors' ability to evaluate the Company's operating costs, comprehensive loss and loss per share, and to compare them to historical Company results.
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company's business internally and therefore decided to make these non-GAAP adjustments available to investors. The non-GAAP financial measures used by the Company in this press release may be different from the measures used by other companies.
For more information on the non-GAAP financial measures, please see the "Reconciliation of GAAP to Non-GAAP Financial Measures" table on page 10 in this press release. This accompanying table on page 10 has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.
The Company's consolidated financial results as of, and for the six months ended, June 30, 2020 are presented in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.
Our products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and, we believe, are ushering in a new era in regenerative and aesthetic medicine.
Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, we entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.
In January 2020, we also entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which we and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. Our industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.
For more information about CollPlant, visit http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the outbreak of coronavirus; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
Sophia Ononye-Onyia, PhD MPH MBA Founder &
CEO, The Sophia Consulting Firm
Tel: +1-347-533-4578
E-mail: sophia@sophiaconsultingfirm.com
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||||||||||
Six months ended | Three months ended | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
U.S. dollars in thousands, except per share data | ||||||||||||||||
Revenue from product sales | $ | 1,228 | $ | 1,048 | $ | 713 | $ | 606 | ||||||||
Revenue from service | 204 | 152 | 110 | - | ||||||||||||
Total Revenue | 1,432 | 1,200 | 823 | 606 | ||||||||||||
Cost of Revenue | 1,223 | 883 | 748 | 463 | ||||||||||||
Gross Profit | 209 | 317 | 75 | 143 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development, net | 1,812 | 1,856 | 1,002 | 1,084 | ||||||||||||
General, administrative and marketing | 2,017 | 1,749 | 986 | 820 | ||||||||||||
Total operating loss | 3,620 | 3,288 | 1,913 | 1,761 | ||||||||||||
Financial income | 26 | 48 | 9 | 630 | ||||||||||||
Financial expenses | (6) | (6) | (2) | (6) | ||||||||||||
Exchange differences | 28 | (242) | (65) | (111) | ||||||||||||
Financial income (expenses), net | 48 | (200) | (58) | 513 | ||||||||||||
Loss for the period | $ | 3,572 | $ | 3,488 | $ | 1,971 | $ | 1,248 | ||||||||
Basic and diluted loss per ordinary share | $ | 0.52 | $ | 0.75 | $ | 0.28 | $ | 0.27 | ||||||||
Weighted average ordinary shares outstanding | 6,809,666 | 4,660,862 | 6,958,109 | 4,661,506 | ||||||||||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
June 30, | December 31, | |||||||
2020 | 2019 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 3,672 | $ | 3,791 | ||||
Trade receivables | 321 | 79 | ||||||
Other accounts receivable and prepaid expenses | 750 | 270 | ||||||
Restricted deposit | 12 | 12 | ||||||
Inventory | 730 | 888 | ||||||
Total current assets | 5,485 | 5,040 | ||||||
Non-current assets: | ||||||||
Restricted deposit | 167 | 168 | ||||||
Operating lease right-of-use assets | 3,048 | 3,215 | ||||||
Property and equipment, net | 2,248 | 2,329 | ||||||
Total non-current assets | 5,463 | 5,712 | ||||||
Total assets | $ | 10,948 | $ | 10,752 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
June 30, | December 31, | |||||||
2020 | 2019 | |||||||
Liabilities and shareholders' equity | ||||||||
Current liabilities: | ||||||||
Loan | $ | 12 | $ | 24 | ||||
Accounts payable: | ||||||||
Trade payables | 559 | 833 | ||||||
Accrued liabilities and other | 866 | 1,203 | ||||||
Operating lease liabilities | 442 | 455 | ||||||
Deferred revenues | 297 | 942 | ||||||
Total current liabilities | 2,176 | 3,457 | ||||||
Non-current liabilities: | ||||||||
Derivatives | 42 | 68 | ||||||
Operating lease liabilities | 2,953 | 3,139 | ||||||
Total non-current liabilities | 2,995 | 3,207 | ||||||
Total liabilities | 5,171 | 6,664 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity: | ||||||||
Ordinary shares, NIS 1.5 par value - authorized: 30,000,000 ordinary shares as of June | 2,713 | 2,368 | ||||||
Additional paid in capital and warrants | 74,865 | 69,949 | ||||||
Currency translation differences | (969) | (969) | ||||||
Accumulated deficit | (70,832) | (67,260) | ||||||
Total shareholders' equity | 5,777 | 4,088 | ||||||
Total liabilities and shareholders' equity | $ | 10,948 | $ | 10,752 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
Six months ended | ||||||||
2020 | 2019 | |||||||
Cash flows from operating activities: | ||||||||
Net cash used in operations (see Appendix A) | $ | (4,343) | $ | (2,725) | ||||
Net cash used in operating activities | (4,343) | (2,725) | ||||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (246) | (1,060) | ||||||
Net cash used in investing activities | (246) | (1,060) | ||||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of shares, net | 4,400 | - | ||||||
Exercise of options into shares | 67 | 7 | ||||||
Loan paid | (12) | (8) | ||||||
Payments made for equipment on financing terms | - | (17) | ||||||
Net cash provided by (used in) financing activities | 4,455 | (18) | ||||||
Decrease in cash and cash equivalents and restricted deposits | (134) | (3,803) | ||||||
Cash and cash equivalents and restricted deposits at the beginning of the period | 3,971 | 5,663 | ||||||
Exchange differences on cash and cash equivalents and restricted deposits | 14 | 54 | ||||||
Cash and cash equivalents and restricted deposits at the end of the period | $ | 3,851 | $ | 1,914 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
Six months ended | ||||||||
2020 | 2019 | |||||||
Appendix to the statement of cash flows | ||||||||
A. Net cash used in operations: | ||||||||
Loss | $ | (3,572) | $ | (3,488) | ||||
Adjustments for: | ||||||||
Depreciation | 327 | 228 | ||||||
Share-based compensation to employees and consultants | 794 | 629 | ||||||
Exchange differences on cash and cash equivalents | (14) | (54) | ||||||
Financial expenses related to financial instruments | (26) | 60 | ||||||
Net change of operating lease accounts | (32) | 292 | ||||||
(2,523) | (2,333) | |||||||
Changes in operating asset and liability items: | ||||||||
Increase in trade receivables | (242) | (95) | ||||||
Decrease (increase) in inventory | 158 | (144) | ||||||
Decrease (increase) in other receivables (including long-term receivables) | (480) | 11 | ||||||
Increase (decrease) in trade payables (including long-term payables) | (274) | 156 | ||||||
Increase (decrease) in accrued liabilities and other payables | (337) | 91 | ||||||
Decrease in deferred revenues (including long term deferred revenues) | (645) | (411) | ||||||
(1,820) | (392) | |||||||
Net cash used in operations | $ | (4,343) | $ | (2,725) | ||||
Supplemental disclosures of non-cash investing and financing activities: | ||||||||
Conversion of pre-paid warrants to ordinary shares | 137 | - | ||||||
Obtaining right of use assets in exchange for a lease liability | 23 | - | ||||||
Classification of warrants from equity to liabilities, net | - | 1,804 | ||||||
CollPlant Biotechnologies Ltd. | ||||||||||||||||
Six months ended | Three months ended | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
USD in thousands | ||||||||||||||||
GAAP gross profit | $ | 209 | $ | 317 | $ | 75 | $ | 143 | ||||||||
GAAP operating costs and expenses: | 3,829 | 3,605 | 1,988 | 1,904 | ||||||||||||
Change of operating lease accounts | 32 | (292) | (87) | (88) | ||||||||||||
Share-based compensation to employees, directors and | (794) | (629) | (477) | (289) | ||||||||||||
Non-GAAP operating costs and expenses: | 3,067 | 2,684 | 1,424 | 1,527 | ||||||||||||
GAAP operating loss | 3,620 | 3,288 | 1,913 | 1,761 | ||||||||||||
Non-GAAP operating loss | 2,858 | 2,367 | 1,349 | 1,384 | ||||||||||||
GAAP Comprehensive loss | 3,572 | 3,488 | 1,971 | 1,248 | ||||||||||||
Change in fair value of financial instruments | 26 | (60) | 9 | 579 | ||||||||||||
Change of operating lease accounts | 32 | (292) | (87) | (88) | ||||||||||||
Share-based compensation to employees, directors and consultants | (794) | (629) | (477) | (289) | ||||||||||||
Non-GAAP Comprehensive loss | $ | 2,836 | $ | 2,507 | $ | 1,416 | $ | 1,450 | ||||||||
GAAP Basic and diluted loss per ordinary share | $ | 0.52 | $ | 0.75 | $ | 0.28 | $ | 0.27 | ||||||||
Non-GAAP Basic and diluted loss per ordinary share | $ | 0.42 | $ | 0.54 | $ | 0.20 | $ | 0.31 | ||||||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-second-quarter-q2-2020-financial-results-301120218.html
SOURCE CollPlant
FAQ
What were CollPlant's Q2 2020 earnings results?
What is the cash position of CollPlant as of June 30, 2020?
What partnerships has CollPlant formed recently?
What are CollPlant's plans for new products?
How did CollPlant's operating expenses change in Q2 2020?
